Medications That Can Increase Prostate Size
The evidence provided does not identify any medications that cause prostate enlargement; rather, the literature focuses exclusively on medications that treat or reduce prostate size in benign prostatic hyperplasia (BPH).
Key Findings from the Evidence
The 2023 European Association of Urology Guidelines and 2021 AUA Guidelines 1, 2 comprehensively discuss pharmacologic management of BPH but do not mention medications that increase prostate size. Instead, they detail:
Medications That Reduce Prostate Size:
- 5-alpha reductase inhibitors (5-ARIs): Finasteride and dutasteride actively shrink the prostate by 15-25% at six months by blocking conversion of testosterone to dihydrotestosterone (DHT) 2
- Alpha-blockers (tamsulosin, alfuzosin, terazosin, doxazosin, silodosin): These do NOT affect prostate volume 1 but improve symptoms by relaxing prostatic smooth muscle
Testosterone and Prostate Growth - A Nuanced Relationship:
Contrary to older dogma, testosterone replacement therapy (TRT) does not appear to worsen prostate enlargement or LUTS 3. In fact, hypogonadism (low testosterone) may itself be a risk factor for LUTS/BPH 3. This challenges the historical assumption that higher testosterone directly causes prostatic growth.
Clinical Implications
If you are asking this question because a patient has worsening BPH symptoms, you should focus on:
- Medication review for drugs that worsen urinary symptoms (anticholinergics, decongestants, antihistamines) rather than those that enlarge the prostate
- Natural disease progression: BPH naturally progresses with age, particularly in men with larger baseline prostate volumes (>30cc) or PSA >1.5 ng/mL 2
- Watchful waiting vs. active treatment: The evidence supports alpha-blockers for symptom relief and 5-ARIs for volume reduction in appropriately selected patients 1, 2
Important Caveat
The provided evidence base is limited to BPH treatment literature. If there are medications that cause iatrogenic prostate enlargement, they are not discussed in these major urology guidelines. The absence of such discussion in comprehensive 2023 guidelines 1 and 2021 AUA guidelines 2 suggests this is not a clinically significant phenomenon in routine practice.
Bottom line: Based on current high-quality guidelines, no commonly used medications are recognized as causing prostate enlargement. The focus should be on treating existing BPH with evidence-based therapies rather than identifying causative medications.